Loading...

Bluejay Diagnostics, Inc.

BJDXNASDAQ
HealthcareMedical - Devices
$2.25
$0.73(48.03%)

Bluejay Diagnostics, Inc. (BJDX) Stock Overview

Explore Bluejay Diagnostics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
0.00%
Profit Growth
$-13.09
22.46%
EPS Growth
$-13.09
42.05%
Operating Margin
-3068.42%
30.47%
ROE
-114.23%
22.46%
Dividend Yield
0.00%
Analyst Recommendations data is not available for BJDXAnalyst Recommendations details for BJDX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

CEO

Mr. Indranil Dey

Employees

7

Headquarters

360 Massachusetts Avenue, Acton, MA

Founded

2021

Frequently Asked Questions